3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
80
Completed
28
Active not recruiting
25
Not yet recruiting
19
Terminated
10
Enrolling by invitation
4
Withdrawn
2
No longer available
1
Available
1
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Genitourinary
1
Conditions
Breast Neoplasms
28
Neoplasms
26
Prostatic Neoplasms
22
Colorectal Neoplasms
17
Head and Neck Neoplasms
14
Pancreatic Neoplasms
11
Lung Neoplasms
10
Brain Neoplasms
10
Neoplasm Metastasis
9
Carcinoma, Renal Cell
9
Squamous Cell Carcinoma of Head and Neck
8
Melanoma
8
Carcinoma, Non-Small-Cell Lung
8
Triple Negative Breast Neoplasms
7
Recurrence
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Multiple Myeloma
7
Lymphoma
7
Glioblastoma
7
Ovarian Neoplasms
6
Lymphoma, Follicular
6
Uterine Cervical Neoplasms
5
Urinary Bladder Neoplasms
5
Lymphoma, B-Cell
5
Leukemia, Myeloid, Acute
5
Leukemia
5
Kidney Neoplasms
5
Hematologic Neoplasms
5
Sarcoma
4
Liver Neoplasms
4
Interventions
bemarituzumab
1
Transurethral Resection of Prostate
1
Radiofrequency Ablation
1
Cryosurgery
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Withdrawn
×
Adenocarcinoma
×
1 year
×
Clear all
NCT07237399
2026-05-13
TA-P-OLIM
University Hospital, Ghent
Withdrawn
NCT06967987
2026-01-21
BEMAFLOT
Institut Cancerologie de l'Ouest
Phase 2
Withdrawn